This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

KEYLearning: MDT Collaboration and Optimising Patient Care

KEYTRUDA® (pembrolizumab) Prescribing Information (Great Britain)
KEYTRUDA® (pembrolizumab) Prescribing Information (Northern Ireland)
[External links]

This module of bite sized videos has been created to highlight the importance of collaboration, sharing of knowledge and experience and how the uro-oncology MDT team co-create the right management for the individual patient.

Licensed indication

This module is CPD certified, offering a certificate upon completion.

You will need to be signed in to MSD Connect to download the certificate.

Register or Login to MSD Connect

Watch at least 80% of the way through each of the videos below, in order to be able to download the certificate.

Watch videos below to progress the module

This module is CPD certified, offering a certificate upon completion.

Introduction

Please use the video selection tool on the left to navigate through the module.

Upon watching all videos there are some questions for you to reflect on, which should take around 20 minutes.

We estimate the module will take roughly an hour to complete, and upon completion (if logged in) a CPD certificate will become available and can be downloaded by clicking the CPD logo in the banner above.

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

The importance of collaboration in a uro-oncology MDT

Length: 8:51 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Co-creating a treatment plan for patients with renal cell carcinoma, in a uro-oncology MDT

Length: 19:15 | This video is best viewed in full screen, using the button in the bottom right

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Managing diarrhoea with dose reduction and treatment interruption

Length: 02:42 | This video is best viewed in full screen, using the button in the bottom right

Prof. Tom Powles presents a case study of a 72 year old male who started on KEYTRUDA in combination with axitinib for advanced renal cell carcinoma, 18 months post nephrectomy. Prof. Powles explains the steps he took to manage the grade 1 diarrhoea.

Favourable
72
Male
1
Heavy smoker, osteoarthritis, controlled hypertension

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Managing transaminitis with steroids in a patient with intermediate risk advanced RCC

Length: 02:36 | This video is best viewed in full screen, using the button in the bottom right

Prof. Tom Powles presents a case study of a 32 year old female who started on KEYTRUDA in combination with axitinib, less than a year after an advanced renal cell carcinoma diagnosis. Prof. Powles explains how transaminitis was managed.

Intermediate
32
Female
1
Irritable bowel disease, 3 month history of haematurea

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Treatment of advanced RCC in a patient with liver and bone metastasis

Length: 02:06 | This video is best viewed in full screen, using the button in the bottom right

Prof. Tom Powles presents his treatment decision for a 45 year old male who started on KEYTRUDA in combination with axitinib, 6 months post nephrectomy for rapidly progressing advanced renal cell carcinoma.

Poor
45
Male
1
Nil of note (marathon runner)

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Questions for self-reflective learning

We encourage you to digest the content in the videos by reflecting on the following questions. We estimate this should take around 20 minutes.

Thinking about your own cross functional MDT, what opportunities are there for informal communication and reflective team learning?
How do you identify and manage adverse events with prescribing combination therapies?
How can clinicians support patients to recognise and report adverse events to ensure early intervention management and initiate adverse event protocols?

After reflection please remember to download your CPD certificate by clicking the logo in the banner above (you will need to login).

Adverse events should be reported. Adverse event reporting forms and information can be found at the bottom of this page.

Further information

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Feedback

We welcome any feedback on the module content, or recommendations for future modules. Please submit your message below:

Reference

  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-RCC-00384 | Date of Preparation: March 2022